Cristian Ferri

Cristian Ferri

Auto-generated profile, based on publicly available information

Cristian Ferri

Laboratorio de Genética Hematológica, IMEX, CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Cancer Epidemiology
Verified
Journal Article
Closed access
NWNatalia Weich
Natalia Weich
CFCristian Ferri
Cristian Ferri
BMBeatriz Moiraghi
Beatriz Moiraghi
RBRaquel Bengió
Raquel Bengió
IGIsabel Giere
Isabel Giere
AFAriela F. Fundia
Ariela F. Fundia

7 March 2014 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
MGMariana Gonzalez
Mariana Gonzalez
CBCarlos De Brasi
Carlos De Brasi
CFCristian Ferri
Cristian Ferri
RBRaquel Bengió
Raquel Bengió
MBMichele Bianchini
Michele Bianchini
ILIrene Larripa
Irene Larripa
Patients with chronic myeloid leukemia (CML) can develop disease resistance to tyrosine kinase inhibitor (TKI) therapy, which is mainly attributable to the presence of point mutations in the tyrosine kinase domain of BCR-ABL1. In order to examine suitable markers to monitor treatment efficacy, we investigated transcript expression profiles of genes known to be involved in myeloid cell proliferation, such as CAMKII gamma and KI67, and in protein stability and ultimately cell survival under physiological and stress conditions, such as heat shock proteins HSP70 and HSP90. We studied 101 patients with CML in different stages of disease and with different responses to TKI treatment. The results of quantitative real-time polymerase chain reaction (qPCR) analyses showed that the expression levels of CAMKII gamma, KI67, HSP70 and HSP90 genes were up-regulated at diagnosis, and in cases with signs of treatment resistance both in chronic and advanced phases (accelerated and blastic phases) with respect to chronic phase in remission and healthy donors. When only 56 resistant cases, 31 with mutations (MT) and 25 without mutations (WT), in the BCR-ABL1 tyrosine kinase domain were considered, the transcript expression profile showed an unexpected significant increase in CAMKII gamma and HSP70, and a significant decrease in HSP90 in MT versus WT cases. This differential transcript expression prompted us to design an expression score, log(CAMKII gamma x HSP70/HSP90), which can be used to provide rapid screening to discriminate the presence or absence of mutations in resistant cells and to monitor TKI treatment efficacy in patients with CML.

1 February 2014 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
CFCristian Ferri
Cristian Ferri
MBMichele Bianchini
Michele Bianchini
RBRaquel Bengió
Raquel Bengió
ILIrene Larripa
Irene Larripa

13 May 2014 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
CFCristian A. Ferri
Cristian A. Ferri
MBMichele Bianchini
Michele Bianchini
RBRaquel M. Bengió
Raquel M. Bengió
EMElena B. Moiraghi
Elena B. Moiraghi
MGMariana S. Gonzalez
Mariana S. Gonzalez
ILIrene B. Larripa
Irene B. Larripa

1 July 2016 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
NWNatalia Weich
Natalia Weich
CFCristian Ferri
Cristian Ferri
BMBeatriz Moiraghi
Beatriz Moiraghi
RBRaquel Bengió
Raquel Bengió
IGIsabel Giere
Isabel Giere
AFAriela Fundia
Ariela Fundia

1 April 2019 in Gene
Verified
Journal Article
Closed access
CFC. Ferri
C. Ferri
NWN. Weich
N. Weich
LGL. Gutiérrez
L. Gutiérrez
CBC. De Brasi
C. De Brasi
MBM.R. Bengió
M.R. Bengió
ILI. Larripa
I. Larripa